New Alzheimer’s Mouse Model Better Characterizes Human Disease
April 2, 2012 - Charles River Discovery Research Services (DRS) recently validated the CVN Alzheimer’s mouse line. This model can be used to investigate amyloid beta-based therapies as well as tau, inflammation, symptomatic changes and CBF-related approaches. Through a recent expansion of this colony, CVN mice are now available for studies.
CVN Alzheimer’s mice better reflect the cascade of disease in humans due to the fact that they address early amyloid deposition and inflammation through to later-staged hyperphosphorylated and aggregated native tau pathology.
In comparison to other mouse models of Alzheimer’s, such as the B6; SJL-Tg (APPSWE) 2576kha TG2576, the CVN mouse shows more Alzheimer-related pathologies at an earlier age. In addition, factors not present in the TG2576, like neurovascular involvement, cell death and tau phosphorylation, can be found in the CVN mouse.
CVN Model History
Researchers at the Division of Neurology, Department of Medicine at Duke University Medical Center in conjunction with the Department of Medicine, Stony Brook University developed this mouse line by genetic deletion of nitric oxide synthase 2 (NOS2; iNOS) in APPSwDI mouse strains (Wilcock et al. 2008). Rationale for reducing NOS2 in this mouse was based on the immunosuppression of NOS2 in chronic inflammatory diseases. NOS2 deletion combined with multiple amyloid precursor protein (APP) mutations enhances the pathology and drives the phenotype toward human Alzheimer’s features.
Technical Information About CVN Model
The homozygous bigenic CVN mouse (APPSwDI/NOS2-/-) progresses from Aβ production and amyloid deposition to hyperphosphorylated normal mouse tau at Alzheimer's disease-associated epitopes. The aggregation and redistribution of tau to somatodendritic regions of neurons causes significant neuronal loss (including loss of interneurons), moderate-to-severe cerebral amyloid angiopathy (CAA), and severe learning and memory deficits. Inflammation, another characteristic of human Alzheimer's, is shown in this model by microglial/macrophage activation and expression of certain chemokines and cytokines. Vascular changes, including CAA and related CBF disturbances are detected by multimodal MRI techniques late in the disease progression.
For more information or to inquire about placing a study using this newly validated CVN Alzheimer’s mouse model, please contact us at email@example.com.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
Clinical pathology data can assist you in selecting the most appropriate model for your study and can provide important information on the physiology and health of your research animals.
We are now the exclusive distributor of the TARGATT™ mouse. The TARGATT mouse is a transgenic mouse designed to produce animal models with investigator designed exogenous DNA sequences knocked-in to a specific site.
Jun 10–Jun 13
Visit us in booth #091 to learn more about our recent innovations including expanded diagnostic capabilities, a new online portal connecting clients with their colonies and a deep-rooted commitment to humane care.
May 28–Jun 01
The International Bone and Mineral Society (IBMS) and the Japanese Society for Bone and Mineral Research (JSBMR) are excited to sponsor the second joint scientific meeting by the two organizations.
May 27–May 29
Charles River and the René Remie Surgical Skills Centre (RRSSC) have joined their expertise and are pleased to offer a 3-day surgery training course. Held at the RRSSC in the Netherlands, this training is designed to be very practical and combines lectures with hands-on exercises, ensuring you receive the most comprehensive training experience. This course is recommended for simple procedures only (e.g., simple exeresis, simple catheterizations such as jugular vein or femoral vein, simple ALZET pump implantation, ECG radiotelemetry).
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.